期刊
FUTURE ONCOLOGY
卷 15, 期 9, 页码 929-941出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0745
关键词
everolimus; first-line treatment; immuno-oncology; lenvatinib; pembrolizumab; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor
类别
资金
- Eisai Inc., Woodcliff Lake, NJ, USA
- Merck & Co., Inc., Kenilworth, NJ, USA
- Eisai Inc.
Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC. Methods: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC. Eligible patients must have advanced clear cell RCC and must not have received any prior systemic anticancer therapy. The primary end point is progression-free survival; secondary end points include objective response rate, overall survival, safety, health-related quality of life and pharmacokinetics. Biomarker evaluations are included as exploratory end points.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据